Presentation is loading. Please wait.

Presentation is loading. Please wait.

Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia.

Similar presentations


Presentation on theme: "Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia."— Presentation transcript:

1 Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non–ST- elevation acute coronary syndromes (MERLIN)-TIMI 36 trial  David A. Morrow, MD, MPH, Benjamin M. Scirica, MD, Ewa Karwatowska-Prokopczuk, MD, PhD, Allan Skene, PhD, Carolyn H. McCabe, BS, Eugene Braunwald, MD  American Heart Journal  Volume 152, Issue 2, Pages 400.e1-400.e9 (August 2006) DOI: /j.ahj Copyright © 2006 Mosby, Inc. Terms and Conditions

2 Figure 1 Adverse consequences of Na and Ca overload in ischemia and heart failure. CHF, Congestive heart failure; Abnl, abnormal. Data from Eur Heart J 1994;9 (Supp I): American Heart Journal  , 400.e1-400.e9DOI: ( /j.ahj ) Copyright © 2006 Mosby, Inc. Terms and Conditions

3 Figure 2 Study schema for MERLIN-TIMI 36. UA, Unstable angina; NSTEMI, non–ST-segment elevation MI; sx, symptoms. American Heart Journal  , 400.e1-400.e9DOI: ( /j.ahj ) Copyright © 2006 Mosby, Inc. Terms and Conditions


Download ppt "Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia."

Similar presentations


Ads by Google